{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:18:29Z","timestamp":1768000709018,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004853","name":"The Chinese University of Hong Kong","doi-asserted-by":"publisher","award":["4054725"],"award-info":[{"award-number":["4054725"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cllc.2025.01.007","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T16:38:56Z","timestamp":1736613536000},"page":"e214-e222.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression"],"prefix":"10.1016","volume":"26","author":[{"given":"Wesley K.Y.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin K.S.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giselle P.C.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert H.F.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landon L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frankie","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty W.C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence S.T.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen C.C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony S.K.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6460-5514","authenticated-orcid":false,"given":"Molly S.C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.01.007_bib0001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fonc.2018.00088","article-title":"Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment","volume":"8","author":"Remon","year":"2018","journal-title":"Front Oncol"},{"issue":"26","key":"10.1016\/j.cllc.2025.01.007_bib0002","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS i of Osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.cllc.2025.01.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to Osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.01.007_bib0004","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2025.01.007_bib0005","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.01.007_bib0006","first-page":"249","article-title":"Version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.cllc.2025.01.007_bib0007","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.cllc.2025.01.007_bib0008","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2017.73.9250","article-title":"Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line Gefitinib (IMPRESS): overall survival and biomarker analyses","volume":"35","author":"Mok","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2025.01.007_bib0009","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2021.01.010","article-title":"Combining osimertinib with chemotherapy in EGFR-mutant NSCLC at progression","volume":"22","author":"White","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"16","key":"10.1016\/j.cllc.2025.01.007_bib0010","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-12-0357","article-title":"The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations","volume":"18","author":"Heon","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2025.01.007_bib0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2025.01.007_bib0012","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of Osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.01.007_bib0013","unstructured":"Rybrevant Medical Information. URL: https:\/\/www.jnjmedicalconnect.com\/products\/rybrevant\/medical-content\/rybrevant-use-in-central-nervous-systemcns-metastases"},{"issue":"11","key":"10.1016\/j.cllc.2025.01.007_bib0014","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2025.01.007_bib0015","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2025.01.007_bib0016","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"Jama"},{"issue":"35","key":"10.1016\/j.cllc.2025.01.007_bib0017","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.cllc.2025.01.007_bib0018","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/fon-2023-0602","article-title":"HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI","volume":"20","author":"Mok","year":"2024","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2025.01.007_bib0019","doi-asserted-by":"crossref","first-page":"S1101","DOI":"10.1016\/j.jtho.2021.08.504","article-title":"P47.11 COMPEL: chemotherapy with\/without osimertinib in patients with EGFRm advanced NSCLC and progression on first-line Osimertinib","volume":"16","author":"Sequist","year":"2021","journal-title":"J of Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:12:42Z","timestamp":1749294762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1525730425000075"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.01.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}